Shots:

• Eisai to receive $650M including $200M as R&D expenses and is eligible to receive ~2.45B as milestones along with royalties on sales outside of collaboration territories. The companies will jointly develop & commercialize MORAb-202 and share profits & costs in collaboration territories
• BMS will lead the development & commercialization outside the collaboration territories while Eisai will remain responsible to manufacture & supply MORAb-202 globally
• Eisai is currently evaluating it in 2 studies i.e P-I study in Japan & P-I/II study in the US for FRα-positive solid tumors while companies plan to move into a registrational stage of development in 2022

  Ref: Business Wire | Image: BMS